Site search

Clear filter
2960 results for '' found
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)
/
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in pe
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in pe
/
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium
/
Zenith: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (NCT07181109)
Zenith: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (NCT07181109)
/
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease [MCI to
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease [MCI to
/
DEFINERx050: A Multicentre, Randomized, Open-Label Study of Atezolizumab [Anti-PD-L1 Antibody] Plus Bevacizumab [Anti-VEGF Antibody] as Neo-Adjuvant therapy Versus Active Surveillance in Hepatoce
DEFINERx050: A Multicentre, Randomized, Open-Label Study of Atezolizumab [Anti-PD-L1 Antibody] Plus Bevacizumab [Anti-VEGF Antibody] as Neo-Adjuvant therapy Versus Active Surveillance in Hepatoce
/
Effects of Semaglutide on Myocardial Energetics in People with Obesity: A Pilot Prospective Mechanistic Study (Trial Not Registered)
Effects of Semaglutide on Myocardial Energetics in People with Obesity: A Pilot Prospective Mechanistic Study (Trial Not Registered)
/
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (NCT063
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (NCT063
/
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Plac
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Plac
/
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor [BAFF-R] T-Cell Engager Bispecific Antib
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor [BAFF-R] T-Cell Engager Bispecific Antib
/
2 3 4 5 6